GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

About DD01 DD01 is a proprietary, once-weekly dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors with a half-life of 7-8 days in obese/overweight patients with T2D and MAFLD.

Furthermore, mazdutide, the fastest-developing dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist globally, has ignited significant research interest in the scientific community ...

Glucagon-like peptide 1 receptor agonists are effective pharmacotherapies for the treatment of obesity and related disorders. In metabolic dysfunction-associated steatohepatitis with moderate to ...

Guangdong Zhongsheng Ruichuang Pharmaceutical Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of MASH, obesity, alcohol use disorder (AUD) and alcohol-associated ...

MIT engineers have developed a tiny implantable device that could revolutionize emergency treatment for people with Type 1 ...

Nash is a handsome caramel colored terrier mix. He is two years old and is looking for a family to share his love with. Call Heartland today!

These receptors also have a large cytoplasmic loop that is involved in receptor biosynthesis, assembly, transport, clustering, anchoring and modulation, but its structure is outside the scope of ...

Altimmune, Inc. announced that it will present findings on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist, at the American Diabetes Association’s 85th Scientific Sessions ...